© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 06, 2016, the consensus forecast amongst 2 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jan 13, 2016. The previous consensus forecast advised investors to purchase equity in GW Pharmaceuticals plc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 2 analysts offering 12 month price targets for GW Pharmaceuticals plc have a median target of 4,578.28, with a high estimate of 8,596.56 and a low estimate of 560.00. The median estimate represents a 1,762.98% increase from the last price of 245.75. View Full Financials
Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials
On Dec 07, 2015, GW Pharmaceuticals plc reported 4th quarter 2015 losses of -0.047 per share. This result under-performed the breakeven expectation of the 3 analysts following the company but under-performed last year's 4th quarter results by -0.048.
The next earnings announcement is expected on Feb 10, 2016. View Full Interim Financials
|Average growth rate||-83.16 %|
GW Pharmaceuticals plc reported annual 2015 losses of -0.181 per share on Dec 07, 2015. View Full Annual Financials
|Average growth rate||-100.63 %|
GW Pharmaceuticals plc had 4th quarter 2015 revenues of 5.60m. This missed the 18.33m consensus estimate of the 3 analysts following the company. The same period last year the company did not report revenues. View Full Interim Financials
|Average growth rate||-3.68 %|
GW Pharmaceuticals plc had revenues for the full year 2015 of 28.54m. This was 5.01 % below the prior year's results. View Full Annual Financials
|Average growth rate||-0.18 %|